TRAIL及其受体和Fas-L在卵巢癌组织中的表达

The Expression of TRAIL, TRAIL-R(DR4,DcR1) and Fas-L in Patients with Ovarian Cancer

目的 探讨TRAIL 及其受体在正常卵巢和卵巢癌组织中的表达,以及其与Fas- L 表达的相互关系。方法 用免疫组化法检测37例卵巢癌在2 1例正常卵巢组织TRAIL、TRAIL 受体(DR4、Dc R1)和Fas- L 的表达,并进行两两之间直线相关分析。结果 卵巢癌中DR4和Dc R1的表达均低于正常卵巢组织;高中分化卵巢癌DR4阳性率为(92 .31% )明显高于低分化癌DR4 (5 4 .5 5 % ,P<0 .0 5 ) ,表明卵巢癌分化程度越低,DR4表达也降低;TRAIL与Fas- L 的表达呈明显正相关(r=0 .777)。结论 卵巢癌中DR4和Dc R1表达低于正常卵巢组织,DR4的表达可能与卵巢癌的预后有关,初步提示TRAIL 及其受体相互作用与卵巢癌细胞凋亡有关。

Objective To investigate the apoptosis induced by TRAIL, TRAIL-R and Fas-L in patients with ovarian carcinoma. Methods The expression of TRAIL, TRAIL-R(DR4,DcR1) and Fas-L in ovarian cancer was detected with immunohistochemistry. Results The levels of DR4 and DcR1 expression in ovarian carcinoma were lower than that of normal tissues. The positive rate of DR4 in well-differentiated ovarian carcinoma was significantly higher than that in poorly differentiated ovarian carcinoma (92.31% vs 54.55%, P<0 05). The expression of TRAIL was significantly correlated with that of Fas-L(r=0.777). Conclusion The expressions of DR4 and DcR1 are lower than that of normal tissues, and the expression of DR4 might be a prognostic factor in ovarian cancer.